Citations

Clear

154 citation(s) found for "Levin, G".

The effect of using fecal testing after a negative sigmoidoscopy on the risk of death from colorectal cancer
Doubeni, Chyke A. , Corley, Douglas A. , Schottinger, Joanne E. , Lee, Jeffery K, Ghai, Nirupa R. , Levin, Theodore R. , Zhao, Wei , Saia, Chelsea , Wainwright, Jocelyn V. , Mehta, Shivan J. , Selby, Kevin , Doria‐Rose, V. Paul , Fletcher, Robert H., Saia, Chelsea A , Weiss, Noel S , Jensen, Christopher D. , Zauber, Ann Graham , Doubeni, Chyke A.

Mayo Clinic

Journal of Medical Screening | May 22, 2020 | Volume: 28 | Issue: 2 | Pages: 140-147

10.1177/0969141320921427 | PMID 32438892 Get It

Objective To examine whether receiving a fecal occult blood test after a negative sigmoidoscopy reduced mortality from colorectal cancer. Methods We used a nested case–control design with incidence-density matching in historical cohorts of 1,877,740 50–90-year-old persons during 2006–2012, in an integrated health-system setting. We selected 1758 average risk patients who died from colorectal cancer and 3503 matched colorectal cancer-free persons. Colorectal cancer-specific death was ascertained from cancer and mortality registries. Screening histories were determined from electronic and chart–audit clinical data in the 5- to 10-year period prior to the reference date. We evaluated receipt of subsequent fecal occult blood test within five years of the reference date among patients with negative sigmoidoscopy two to six years before the reference date. Results Of the 5261 patients, 831 patients (204 colorectal cancer deaths/627 controls) had either negative sigmoidoscopy only ( n = 592) or negative sigmoidoscopy with subsequent screening fecal occult blood test ( n = 239). Fifty-six (27.5%) of the 204 patients dying of colorectal cancer and 183 (29.2%) of the 627 colorectal cancer-free patients received fecal occult blood test following a negative sigmoidoscopy. Conditional regressions found no significant association between fecal occult blood test receipt and colorectal cancer death risk, overall (adjusted odds ratio = 0.93, confidence interval: 0.65–1.33), or for right (odds ratio = 1.02, confidence interval: 0.65–1.60) or left-colon/rectum (odds ratio = 0.77, confidence interval: 0.39–1.52) cancers. Similar results were obtained in sensitivity analyses with alternative exposure ascertainment windows or timing of fecal occult blood test. Conclusions Our results suggest that receipt of at least one fecal occult blood test during the several years after a negative sigmoidoscopy did not substantially reduce mortality from colorectal cancer.
CDK12 -Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Antonarakis, Emmanuel S. , Fu, Wei , Santos, Víctor Sacristán , Maughan, Benjamin L. , Пили, Роберто , Vlachostergios, Panagiotis J. , Tagawa, Scott T. , Bryce, Alan H. , McNatty, Andrea, Reichert, Zachery R. , Hussain, Maha , Antonarakis, Emmanuel S. , McNatty, Andrea L, Bryce, Alan H , Antonarakis, Emmanuel S , Tagawa, Scott T , Vlachostergios, Panagiotis J , Hussain, Maha H A , Antonarakis, Emmanuel S , Velho, Pedro Isaacsson , Wang, Hao , Agarwal, Neeraj , Adra, Nabil , Sternberg, Cora N , Dreicer, Robert , Sartor, Oliver , Lotan, Tamara Levin

Mayo Clinic

JCO Precision Oncology | April 21, 2020 | Volume: No volume available | Issue: 4 | Pages: 370-381

10.1200/po.19.00399 | PMID 32462107 Get It

PURPOSE In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly characterize CDK12-aberrant prostate cancers. METHODS We conducted a retrospective multicenter study to identify patients with advanced prostate cancer who harbored somatic loss-of-function CDK12 mutations. We used descriptive statistics to characterize their clinical features and therapeutic outcomes (prostate-specific antigen [PSA] responses, progression-free survival [PFS]) to various systemic therapies, including sensitivity to poly (ADP-ribose) polymerase and PD-1 inhibitors. RESULTS Sixty men with at least monoallelic (51.7% biallelic) CDK12 alterations were identified across nine centers. Median age at diagnosis was 60.5 years; 71.7% and 28.3% were white and nonwhite, respectively; 93.3% had Gleason grade group 4-5; 15.4% had ductal/intraductal histology; 53.3% had metastases at diagnosis; and median PSA was 24.0 ng/mL. Of those who underwent primary androgen deprivation therapy for metastatic hormone-sensitive disease (n = 59), 79.7% had a PSA response, and median PFS was 12.3 months. Of those who received first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer (mCRPC; n = 34), 41.2% had a PSA response, and median PFS was 5.3 months. Of those who received a first taxane chemotherapy for mCRPC (n = 22), 31.8% had a PSA response, and median PFS was 3.8 months. Eleven men received a PARP inhibitor (olaparib [n = 10], rucaparib [n = 1]), and none had a PSA response (median PFS, 3.6 months). Nine men received a PD-1 inhibitor as fourth- to sixth-line systemic therapy (pembrolizumab [n = 5], nivolumab [n = 4]); 33.3% had a PSA response, and median PFS was 5.4 months. CONCLUSION CDK12-altered prostate cancer is an aggressive subtype with poor outcomes to hormonal and taxane therapies as well as to PARP inhibitors. A proportion of these patients may respond favorably to PD-1 inhibitors, which implicates CDK12 deficiency in immunotherapy sensitivity.
Planned induction versus spontaneous delivery among women using prophylactic anticoagulation therapy: a retrospective study
Rottenstreich, Amihai , Zacks, Netanel, Kleinstern, Geffen , Levin, Gabriel , Sompolinsky, Yishay, Mankuta, David, Rottenstreich, Misgav , Levin, G , Rottenstreich, M , Ezra, Yossef , Yagel, Simcha , Kalish, Yosef

Mayo Clinic

BJOG: An International Journal of Obstetrics & Gynaecology | April 13, 2020 | Volume: 127 | Issue: 10 | Pages: 1241-1248

10.1111/1471-0528.16247 | PMID 32281735 Get It

ObjectivesTo examine the outcomes of planned induction of labour versus spontaneous onset of labour among women using prophylactic‐dose low‐molecular weight heparin (LMWH) therapy.DesignRetrospective cohort study.SettingUniversity hospital.PopulationWomen receiving antepartum prophylactic LMWH therapy undergoing a trial of vaginal delivery.MethodsCharts from 2018–2019 were reviewed.Main outcome measuresDuration of anticoagulation interruption and eligibility to receive neuraxial anaesthesia.ResultsData from 199 women were analysed; 78 (39.2%) were admitted following spontaneous onset of labour and 121 (60.8%) underwent planned induction of labour. Compared to women who underwent planned induction of labour, women who presented with spontaneous onset of labour had a shorter median admission‐to‐delivery interval (4.7 versus 29.3 hours, P < 0.001). Similarly, intervals from the last LMWH injection to delivery (25.8 versus 48.2 hours, P < 0.001) and to the first postpartum LMWH injection (41.2 versus 63.7 hours, P < 0.001) were shorter. Among those with spontaneous onset of labour, 69 (88.5%) were eligible to receive neuraxial anaesthesia. Rates of postpartum haemorrhage and blood transfusion were similar between the groups. No thrombotic events were encountered in those with spontaneous onset of labour, but four (3.3%) women who delivered following induction of labour developed a postpartum thrombotic event.ConclusionPlanned induction of labour was associated with a higher risk of postpartum thrombotic events than was spontaneous onset of labour (4 of 121 [3.3%] versus 0 of 78 [0%]), presumably due to prolonged duration of anticoagulation interruption, although the difference was not statistically significant. Allowing spontaneous onset of labour was associated with comparable rates of bleeding complications, and only a low proportion (9 of 78, 11.5%) were not eligible to receive neuraxial anaesthesia.Tweetable abstractPlanned induction among women using prophylactic LMWH therapy might increase the risk of thromboembolic complications.
Impact of initial treatment selection on clinical outcomes after biochemical failure in radiorecurrent high-risk prostate cancer.
Levin-Epstein, Rebecca , Romero, Tahmineh , Wong, J.K. , Demanes, D. Jeffrey, Stish, B.J., Krauss, Daniel , Wedde, Trude B. , Lilleby, Wolfgang , Stock, Richard G. , Steinberg, Michael L. , Horwitz, Eric M. , Tendulkar, Rahul D. , Kishan, Amar U. , Cook, Kiri A. , Dess, Robert T. , Spratt, Daniel E. , Moran, Brian Joseph , Merrick, Gregory Stephen , Tran, Phuoc T , Tward, Jonathan D.

Mayo Clinic

Journal of Clinical Oncology | February 19, 2020 | Volume: 38 | Issue: 6_suppl | Pages: 208-208

10.1200/jco.2020.38.6_suppl.208 Get It

208 Background: Treatment of high risk prostate cancer (HRPCa) with external beam radiotherapy (EBRT) plus brachytherapy (BT) boost (EBRT+BT) has been prospectively associated with lower rates of BCR, albeit potentially with increased toxicity, and retrospectively linked to decreased distant metastasis (DM) and PCa-specific mortality (PCSM) compared to EBRT alone. However, it is unclear whether patients who develop BCR following either approach have similar downstream oncologic outcomes. Methods: We identified 706 out of 3820 men with HRPCa treated at 13 institutions from 1998-2015 with EBRT (n=468/2134) or EBRT+BT (n=238/1686) who developed BCR. We compared rates of DM, PCSM, and all-cause mortality (ACM) after BCR between treatment groups using Fine-Gray competing risk regression. Models were adjusted for age, Gleason grade group, initial PSA (iPSA), clinical T stage, time-dependent use of systemic salvage, and interval to BCR using inverse probability of treatment weighting. Results: Median follow-up was 9.9 years from RT and 4.8 years from BCR. Groups were similar in age, iPSA, presence of ≥2 HR features, and median interval to BCR (3.3 years). Most men received neoadjuvant/concurrent androgen deprivation therapy (ADT), 92.5% and 91.0% for EBRT and EBRT+BT, respectively, though for a longer duration with EBRT (median 14.7 vs. 9.0 months, p=0.0012). Local and systemic salvage rates were 2.3% and 36.3% after EBRT, and 2.6% and 43.6% after EBRT+BT, respectively. Initial EBRT+BT was associated with significantly lower rates of DM after BCR (HR 0.48, 95% CI 0.36-0.64, p<0.001). Rates of PCSM and ACM did not significantly differ (HR 0.93, 95% CI 0.67-1.30, p=0.93, and HR 0.8, 95% CI 0.6-1.1, p=0.11, respectively). Conclusions: In this large retrospective series of radiorecurrent HRPCa, initial treatment with EBRT+BT was associated with significantly lower rates of DM after BCR compared with EBRT, despite shorter ADT use and a similar median interval to BCR. Local salvage was widely underutilized in both groups. In the absence of salvage for local failure after EBRT, upfront treatment intensification with BT may reduce DM, though not PCSM or ACM, even after development of BCR.
Genomic and clinical characterization of stromal infiltration markers in prostate cancer
Mahal, Brandon A. , Alshalalfa, Mohammed , Zhao, Shuang G. , Beltran, Himisha , Chen, William S. , Chipidza, Fallon , Karnes, R. Jeffrey , Ku, Sheng‐Yu , Muralidhar, Vinayak , Schaeffer, Edward M. , Spratt, Daniel E. , Feng, Felix Y. , Nguyen, Paul L. , Spratt, Daniel E , Zhao, Shuang G , Davicioni, Elai , Lotan, Tamara Levin , Rebbeck, Timothy R.

Mayo Clinic

Cancer | January 6, 2020 | Volume: 126 | Issue: 7 | Pages: 1407-1412

10.1002/cncr.32688 | PMID 31905251 Get It

BackgroundThe progression of prostate cancer is a complex, multistep process that involves molecular alterations in cells of the tumor and the microenvironment, with associated interactions between the stroma and epithelium. Genomic expression analyses of stromal infiltration markers were performed to determine the significance thereof in prostate cancer.MethodsGenome‐wide expression profiles of formalin‐fixed, paraffin‐embedded radical prostatectomy samples were evaluated from a prospective registry cohort (n = 5239) and 3 retrospective institutional cohorts (n = 1135). Two independent stromal gene expression signatures implied stromal infiltration. Cox proportional hazards regression defined the association between stromal infiltration expression and metastasis‐free survival (MFS).ResultsStromal expression scores were correlated with stromal signature genes and with other key stromal markers (CAV1, VIM, and TAGLN), basal activity, and CD3 and CD4 immune biomarkers (r > 0.5 for all). The top decile of stromal expression was associated with high genomic risk scores (Decipher ≥ 0.6) , high Cancer of the Prostate Risk Assessment–Postsurgical scores, Gleason 9 to 10 disease, and a higher risk for metastasis (hazard ratio, 2.35; 95% CI, 1.37‐4.02; P = .001). A higher stromal infiltration score was also associated with decreased expression of DNA repair genes and higher radiation sensitivity genomic scores. Postoperative radiation therapy (RT) was associated with an MFS benefit for patients with high stromal scores, but not for patients with low stromal scores (Pinteraction = .02).ConclusionsExpression of stromal infiltration markers is correlated with prostate cancer aggressiveness/progression and may be predictive of a response to RT. Stromal infiltration markers should be studied and considered for incorporation into clinical prognostication and decision making.
The Effectiveness of Combinations of Antileukemic Agents in Inducing and Maintaining Remission in Children with Acute Leukemia
Frei, Emil, Karon, Myron, Levin, Robert H., Freireich, Emil J., Taylor, Robert , Hananian, Juliet, Selawry, Oleg S., Holland, James F., Hoogstraten, Barth, Wolman, Irving J., Abir, Esshagh, Sawitsky, A, MILLS, STEPHAN D., Burgert, E. Omer, Spurr, Charles L., Patterson, Richard B., Ebaugh, Franklin G., James, G. Watson, Moon, John H., Lee, Stanley Chun-Wei , MILLS, STEPHAN D.

Mayo Clinic

Blood | October 12, 2019 | Volume: 26 | Issue: 5 | Pages: 642-656

10.1182/blood.v26.5.642.642 Get It

Abstract 1. Combinations of effective agents produce at least an additive increase in complete remission rates over that which can be achieved when the agents are used individually. 2. Patients who do not achieve complete remission with initial treatment have a significantly shorter survival. 3. Alternating MTX and 6-MP at 28-day intervals during remission does not prolong the duration of remission over that of combined concurrent 6-MP and MTX. 4. The administration of folic acid antagonists intrathecally at 28-day intervals during antimetabolite maintained remission did not prolong the duration of remission. Meningeal leukemia, however, occurred significantly less frequently in these patients. 5. The duration of combined 6-MP and MTX maintained remission is not greater than that of 6-MP maintained remission. 6. The toxicity of 6-MP and MTX in combination in patients in remission is additive. The above conclusions were drawn from this comparative study of combinations of chemotherapeutic agents in children with acute lymphocytic leukemia.
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Spratt, Daniel E. , Alshalalfa, Mohammed , Fishbane, Nick , Weiner, Adam B. , Mehra, Rohit , Mahal, Brandon A. , Lehrer, Jonathan , Zhao, Shuang G. , Speers, Corey , Morgan, Todd M. , Dicker, Adam P. , Freedland, Stephen J. , Karnes, R. Jeffery, Weinmann, Sheila , Ross, Ashley E. , Nguyen, Paul L. , Feng, Felix Y. , Chinnaiyan, Arul M., Schaeffer, Edward M. , Speers, Corey , Davicioni, Elai , Den, Robert B , Spratt, Daniel E , Morgan, Todd M , Dicker, Adam P , Liu, Yang , Zhao, Shuang G , Karnes, R. Jeffrey , Davicioni, Elai , Den, Robert B. , Lotan, Tamara Levin

Mayo Clinic

Clinical Cancer Research | September 12, 2019 | Volume: 25 | Issue: 22 | Pages: 6721-6730

10.1158/1078-0432.ccr-19-1587 | PMID 31515456 Get It

Abstract Purpose: The heterogeneity of androgen receptor (AR)-activity (AR-A) is well-characterized in heavily treated metastatic castration-resistant prostate cancer (mCRPC). However, the diversity and clinical implications of AR-A in treatment-naïve primary prostate cancer is largely unknown. We sought to characterize AR-A in localized prostate cancer and understand its molecular and clinical implications. Experimental Design: Genome-wide expression profiles from prostatectomy or biopsy samples from 19,470 patients were used, all with independent pathology review. This was comprised of prospective discovery (n = 5,239) and validation (n = 12,728) cohorts, six retrospective institutional cohorts with long-term clinical outcomes data (n = 1,170), and The Cancer Genome Atlas (n = 333). Results: A low AR-active subclass was identified, which comprised 9%–11% of each cohort, and was characterized by increased immune signaling, neuroendocrine expression, and decreased DNA repair. These tumors were predominantly ERG and basal subtype. Low AR-active tumors had significantly more rapid development of recurrence or metastatic disease across cohorts, which was maintained on multivariable analysis [HR, 2.61; 95% confidence interval (CI), 1.22–5.60; P = 0.014]. Low AR-active tumors were predicted to be more sensitive to PARP inhibition, platinum chemotherapy, and radiotherapy, and less sensitive to docetaxel and androgen-deprivation therapy. This was validated clinically, in that low AR-active tumors were less sensitive to androgen-deprivation therapy (OR, 0.41; 95% CI, 0.21–0.80; P = 0.008). Conclusions: Leveraging large-scale transcriptomic data allowed the identification of an aggressive subtype of treatment-naïve primary prostate cancer that harbors molecular features more analogous to mCRPC. This suggests that a preexisting subgroup of patients may have tumors that are predisposed to fail multiple current standard-of-care therapies and warrant dedicated therapeutic investigation.
PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D‐VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK
Spencer, Andrew , Lentzsch, Suzanne , Spicka, I., Lauri, Birgitta, Lee, J.‐J., Nooka, A., Munder, Markus , Lee, C., Barreto, Wolney, Min, Chang‐Ki , Chanan‐Khan, A.A., Horvath, Noemi , Capra, Marcelo , Ovilla, Roberto, Jo, Jin-Hyeong, Shin, Ho‐Jin , Sonneveld, Pieter , Soong, David, Casneuf, Tineke, Ukropec, Jon, Qi, Ming , Mateos, M.‐V., Weisel, Katja C , Avet‐Loiseau, Hervé , Mark, Tomer M , Spicka, I., Masszi, Tamás , Levin, Mark-David , Bosi, Alberto , Hungria, Vânia , Cavo, Michèle , Quach, Hang , Corradini, Paolo , Beksaç, Meral , Chiu, C., Amin, H., Qi, M.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 251

10.1097/01.hs9.0000560672.85259.7d Get It

Background:Patients (pts) with multiple myeloma associated with high cytogenetic risk abnormalities have poor outcomes. In CASTOR, D‐Vd prolonged progression‐free survival (PFS) vs bortezomib and dexamethasone (Vd) alone, and exhibited a manageable safety profile in pts with RRMM. We conducted a subgroup analysis of D‐Vd vs Vd in CASTOR, based on cytogenetic risk.Aims:The purpose of this analysis was to determine the efficacy and safety of D‐Vd in CASTOR based on cytogenetic risk status.Methods:Eligible pts received ≥1 prior line of therapy. Cytogenetic risk was based on a combined analysis of next‐generation sequencing (NGS) and fluorescence in situ hybridization (FISH)/karyotype testing. High‐risk pts had t(4;14), t(14;16), or del17p abnormalities. Standard (std)‐risk pts were confirmed negative for all 3 abnormalities. Minimal residual disease (MRD; 10–5) was assessed via NGS using clonoSEQ® assay V2.0.Results:In CASTOR (D‐Vd, n = 251; Vd, n = 247), high‐risk was confirmed in 26.7% and 25.9% of pts in the D‐Vd and Vd groups, respectively. At a median follow up of 40.0 months (mo), D‐Vd prolonged PFS vs Vd in pts with high‐ (median 13.4 vs 7.2 mo; HR, 0.40 [95% CI, 0.24–0.65]; P = 0.0002) or std‐risk (median 18.4 vs 6.8 mo; HR, 0.28 [95% CI, 0.20–0.37]; P <0.0001). Higher ORR was seen with D‐Vd vs Vd (high risk: 84.8% vs 60.0%; P = 0.0226; std risk: 85.4% vs 65.0%; P <0.0001), including deep responses of ≥CR (high risk: 33.3% vs 8.3%; std risk: 29.9% vs 10.2%) and ≥VGPR (high risk: 65.2% vs 35.0%; P = 0.0049; std risk: 64.3% vs 28.0%; P <0.0001). Higher rates of MRD negativity (high risk: 17.9% vs 0%; P = 0.0003; std risk: 13.3% vs 2.4%; P = 0.0003), and sustained MRD negativity for ≥6 mo (high risk: 16.4% vs 0%; P = 0.0006; std risk: 6.1% vs 1.8%; P = 0.0859) and ≥12 mo (high risk: 7.5% vs 0%; P = 0.0581; std risk: 1.8% vs 0%; P = 0.2477) were seen with D‐Vd vs Vd. D‐Vd significantly prolonged PFS vs Vd in pts with one prior line of therapy only (high risk: median 20.1 vs 8.4 mo; HR, 0.30 [95% CI, 0.14–0.64]; P = 0.0012; std risk: median 32.6 vs 7.9 mo; HR, 0.18 [95% CI, 0.11–0.29]; P <0.0001; Figure). Additionally, D‐Vd significantly prolonged PFS2 (high risk: median 27.9 vs 18.6 mo; HR, 0.59 [95% CI, 0.37–0.94]; P = 0.0258; std risk: median 40.1 vs 21.6 mo; HR, 0.43 [95% CI, 0.32–0.59]; P <0.0001) regardless of cytogenetic risk status.Additional data including safety analyses will be presented.Summary/Conclusion:Adding daratumumab to Vd demonstrates significant efficacy in pts with high‐risk RRMM including PFS2. Among high‐risk RRMM pts, MRD negativity was only achieved with D‐Vd. These findings support use of D‐Vd for high‐risk RRMM. NCT02136134image
Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer
Salami, Simpa S. , Kaplan, Jeremy , Nallandhighal, Srinivas , Takhar, Mandeep, Tosoian, Jeffrey J. , Lee, Matthew , Yoon, Junhee, Plouffe, Komal , Kaffenberger, Samuel D. , Schaeffer, Edward M. , Karnes, R. Jeffrey , George, Arvin K. , Montgomery, Jeffrey S., You, Sungyong , Tomlins, Scott A. , Curci, Nicole E. , Kim, Hyung L. , Spratt, Daniel E. , Palapattu, Ganesh S. , Spratt, Daniel E , Kim, Hyung L , Salami, Simpa S , Hovelson, Daniel H. , Lotan, Tamara Levin , Morgan, Todd M. , Davenport, Matthew S. , Udager, Aaron M , Lee, Matthew S

Mayo Clinic

JCO Precision Oncology | June 12, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-12

10.1200/po.19.00054 | PMID 32914029 Get It

PURPOSE Multiparametric magnetic resonance imaging (mpMRI) is used widely for prostate cancer (PCa) evaluation. Approximately 35% of aggressive tumors, however, are not visible on mpMRI. We sought to identify the molecular alterations associated with mpMRI-invisible tumors and determine whether mpMRI visibility is associated with PCa prognosis. METHODS Discovery and validation cohorts included patients who underwent mpMRI before radical prostatectomy and were found to harbor both mpMRI-visible (Prostate Imaging and Reporting Data System 3 to 5) and -invisible (Prostate Imaging and Reporting Data System 1 or 2) foci on surgical pathology. Next-generation sequencing was performed to determine differential gene expression between mpMRI-visible and -invisible foci. A genetic signature for tumor mpMRI visibility was derived in the discovery cohort and assessed in an independent validation cohort. Its association with long-term oncologic outcomes was evaluated in a separate testing cohort. RESULTS The discovery cohort included 10 patients with 26 distinct PCa foci on surgical pathology, of which 12 (46%) were visible and 14 (54%) were invisible on preoperative mpMRI. Next-generation sequencing detected prioritized genetic mutations in 14 (54%) tumor foci (n = 8 mpMRI visible, n = 6 mpMRI invisible). A nine-gene signature (composed largely of cell organization/structure genes) associated with mpMRI visibility was derived (area under the curve = 0.89), and the signature predicted MRI visibility with 75% sensitivity and 100% specificity (area under the curve = 0.88) in the validation cohort. In the testing cohort (n = 375, median follow-up 8 years) there was no significant difference in biochemical recurrence, distant metastasis, or cancer-specific mortality in patients with predicted mpMRI-visible versus -invisible tumors (all P > .05). CONCLUSION Compared with mpMRI-invisible disease, mpMRI-visible tumors are associated with underexpression of cellular organization genes. mpMRI visibility does not seem to be predictive of long-term cancer outcomes, highlighting the need for biopsy strategies that detect mpMRI-invisible tumors.